OptimizeRx Corp (OPRX) Form 8-K — Aug 12, 2026
$OPRXForm 8-KItems 2.02, 5.02, 7.01, 9.01Filed Aug 12, 2026, 4:07 PM ET0001448431-26-000014Original filing
OptimizeRx reported Q2 2026 revenue of $20.5 million, down 30% from $29.2 million a year earlier, swinging to a GAAP net loss of $0.7 million ($0.04 per share) from $1.5 million in net income. Adjusted EBITDA was $4.9 million and non-GAAP net income $3.1 million ($0.16 per diluted share), and management said revenue and adjusted EBITDA exceeded consensus while reiterating FY2026 guidance of $95-100 million in revenue and $21-25 million in adjusted EBITDA.
Key figures
- Revenue
- 20500000
- Guidance
- Reaffirmed FY2026 revenue of $95-100 million and adjusted EBITDA of $21-25 million
- Debt Amount
- $35 million banking facility, including $25 million term loan and $10 million undrawn revolver
- Revenue Yoy
- -30%
- Cash Position
- 24096000
- Dsilva base salary
- 375000
- Favazza base salary
- 325000
- Term loan paid in q2
- 5300000
- Net revenue retention
- 90% vs 121% year-ago
- Adjusted ebitda q2 2025
- 5769000
- Adjusted ebitda q2 2026
- 4938000
- Stelmakh bonus lump sum
- 247500
- Severance expenses q2 2026
- 1714000
- Top20 pharma revenue share
- 54% vs 59% year-ago
- Non gaap net income q2 2026
- 3106000
- Non gaap eps diluted q2 2026
- 0.16
- Stelmakh salary continuation
- 450000
- Additional repayment post quarter
- 3000000
- Term loan principal repaid since inception
- 8300000
Price after filing
1 day: +24.7%7 days: +13.8%30 days: +3.6%
Close on the filing date to close N calendar days later (from $7.04). Historical, not a forecast.
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.